Please ensure Javascript is enabled for purposes of website accessibility

FDA Tells Healthcare Providers: Stop Treating COVID-19 Outpatients with Malaria Drugs

By Cory Renauer – Apr 24, 2020 at 4:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare regulator says that hydroxychloroquine and chloroquine are causing dangerous heart issues in coronavirus patients.

The Food and Drug Administration on Friday issued a safety warning to healthcare providers, instructing them to stop prescribing hydroxychloroquine and chloroquine to people with COVID-19 being treated on an outpatient basis. The health regulator cited reports of serious heart rhythm problems among coronavirus patients who had been treated with the drugs, which were originally used to fight malaria, a parasitic disease.

Evidence on the way

The two drugs in question are synthetic analogs of quinine, a compound that was extracted from tree bark and used as an antimalarial for centuries. More recently, quinine analogs have been shown to provide a variety of benefits beyond parasite prophylaxis, mainly as treatments for lupus and other serious autoimmune disorders.

Healthcare professional with their hand up.

Image source: Getty Images.

Novartis (NVS -1.84%) markets hydroxychloroquine, and the global pharmaceutical giant is currently running a study with COVID-19 patients randomized into groups receiving either the drug or a placebo. At the moment, though, there's nothing but anecdotal evidence to suggest quinine analogs effectively fight the coronavirus.

And indeed, this week, the Veterans Administration reported on a retrospective study it conducted, that found COVID-19 patients who had been treated with hydroxychloroquine had a significantly higher death rate than those who had not. But that was not a randomized clinical trial, so it may be too soon to write the treatment off.  

Wait for it 

Hydroxychloroquine hasn't been proven effective at fighting other lethal coronaviruses that invade the respiratory system. Unfortunately, the malaria drug has been shown to cause abnormal heart rhythms that lead to fainting, seizures, and sometimes death.

Risk of life-threatening heart conditions such as QT interval prolongation is also a reason not to take azithromycin unless you're near people who can help your heart regain a steady beat. Since that antibiotic is often given to coronavirus patients to prevent secondary infections, the possibility that the combination could cause a bad reaction among patients who are especially vulnerable is a huge risk to consider. 

If clinical trial results from Novartis show a strong benefit, the FDA will quickly adjust its recommendations. Until then, healthcare providers need to treat quinine analogs as too risky for patients outside of a hospital setting.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
NVS
$74.61 (-1.84%) $-1.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.